Search results
Results from the WOW.Com Content Network
Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...
(Reuters) -Shares of British drugmaker GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer ...
British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
The sale will bring down GSK's current 10.3% holding in the Sensodyne maker, which was spun out and listed on the London Stock Exchange in July 2022. GSK earlier this year sold 240 million shares ...
On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales. ... News. Shopping. Main Menu ...